Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
We describe here a case of nivolumab-induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.